Advances in cell therapies for Parkinson’s, GLP-1 agonists and dementia risk, FDA accelerated approvals for neurology drugs
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to Cart failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Please try again
Unfollow podcast failed
Please try again
Advances in cell therapies for Parkinson’s, GLP-1 agonists and dementia risk, FDA accelerated approvals for neurology drugs
-
Narrated by:
-
By:
About this listen
In this episode, editor-in-chief Joseph E. Safdieh, MD, FAAN, highlights articles about early studies finding dopamine cellular therapies were safe and tolerable for patients with Parkinson’s, use of GLP-1 agonists were associated with reduced dementia risks, and the FDA use of accelerated approvals for several neurology drugs are under scrutiny.
adbl_web_global_use_to_activate_T1_webcro805_stickypopup
No reviews yet